Citigroup Inc Beam Therapeutics Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 259,186 shares of BEAM stock, worth $6.07 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

259,186

Previous 187,588 38.17%

Holding current value

$6.07 Million

Previous $5.11 Million 67.7%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$23.46 - $45.07 $1.68 Million - $3.23 Million	71,598 Added 38.17%	259,186 $8.56 Million
Q4 2023 Feb 09, 2024	SELL	$17.69 - $30.76 $177,059 - $307,876	-10,009 Reduced 5.07%	187,588 $5.11 Million
Q3 2023 Nov 09, 2023	BUY	$23.01 - $32.46 $804,038 - $1.13 Million	34,943 Added 21.48%	197,597 $4.75 Million
Q2 2023 Aug 10, 2023	SELL	$29.32 - $35.99 $1.67 Million - $2.05 Million	-56,847 Reduced 25.9%	162,654 $5.19 Million
Q1 2023 May 11, 2023	BUY	$30.15 - $48.79 $3.09 Million - $5 Million	102,451 Added 87.53%	219,501 $6.72 Million

Q4 2022 Feb 09, 2023	SELL	$36.73 - $51.6 $665,327 - $934,682	-18,114 Reduced 13.4%	117,050 $4.58 Million
Q3 2022 Nov 10, 2022	SELL	$39.79 - $70.31 $760,148 - $1.34 Million	-19,104 Reduced 12.38%	135,164 $6.44 Million
Q2 2022 Aug 10, 2022	BUY	$29.86 - $62.36 $3.09 Million - $6.46 Million	103,543 Added 204.13%	154,268 $5.97 Million
Q1 2022 May 12, 2022	SELL	$53.73 - $82.16 $1.97 Million - $3.01 Million	-36,578 Reduced 41.9%	50,725 $2.91 Million
Q4 2021 Feb 10, 2022	BUY	$68.02 - $99.06 $3.2 Million - $4.65 Million	46,989 Added 116.56%	87,303 $6.96 Million
Q3 2021 Nov 10, 2021	BUY	$84.37 - $133.6 $3.4 Million - $5.39 Million	40,314 New	40,314 $3.51 Million

Others Institutions Holding BEAM

# of Institutions

241

Shares Held

65.6M

Call Options Held

311K

Put Options Held

777K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.65B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account